|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, these findings suggest that the CD70-CD27 pathway enhances the malignant phenotypes of MPM and diminishes anti-tumor immune response in patients with these neoplasms.
|
31639216 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD70-CD27 pathway-modulating therapies may be applied to CRC patients regardless of their tumor MMR status.
|
30980190 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The protein expression of CD27 quantified with ELISA had a strong correlation with its mRNA expression in NSCLC tumors (Spearman coefficient = 0.494, P < 0.0088).
|
29861409 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A homologous, all murine anti-CD70 CAR model was also used to assess treatment-related toxicities.<b>Results:</b> The CAR consisting of the extracellular binding portion of CD27 fused with 41BB and CD3-zeta (trCD27-41BB-zeta) conferred the highest IFNγ production against CD70-expressing tumors <i>in vitro</i>, and NSG mice bearing established CD70-expressing human tumors could be cured by human lymphocytes transduced with this CAR.
|
27803044 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review focuses on the role of CD27 co-stimulation in anti-viral T-cell immunity and discusses clinical studies utilising the CD27 co-stimulation pathway for anti-viral, anti-tumour and autoimmune immunotherapy.
|
28086150 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD27 and CD40 costimulatory molecules and TILs expressing activation marker CD38 in the tumour were also correlated with patient survival.
|
26669617 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of CD27-trunc on malignant cells increased the number of tumor-infiltrating interferon γ-producing natural killer (NK) cells.
|
28495792 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we found that natural peptide vaccination induced tumor-reactive CD8 T cells with frequent coexpression of both memory/homing-associated genes (CD27, IL7R, EOMES, CXCR3, and CCR5) and effector-related genes (IFNG, KLRD1, PRF1, and GZMB), comparable with protective Epstein-Barr virus-specific and cytomegalovirus-specific T cells.
|
22735807 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using an in vivo model of tumor immunity, we show here that CD11b(hi)CD27(low) NK cells migrate to the tumor site to reject major histocompatibility complex class I negative tumors, a response that is severely impaired in Txb21(-/-) mice.
|
21389319 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using flow cytometry analysis, we confirmed the expression of the tumor-reactive, TGF-beta-insensitive CD8(+) T cells were the effector CD8(+) cells (CD27(-)CDRA(+)).
|
20028741 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cells with the phenotype of tumor plasma cells (CD38(++)CD19(-)CD45(-/+)CD56(-/+/++)) or memory B cells (CD38(-)/CD19(+)/CD27(+)) were isolated by flow activated cell sorting.
|
20511669 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, studies conducted on tumor-infiltrating lymphocyte (TIL) samples that were administered to melanoma patients indicated that the size of the pool of CD27(+)CD8(+) T cells in bulk TILs was highly associated (p = 0.004) with the ability of these TILs to mediate tumor regression following adoptive transfer.
|
16751420 |
2006 |